BioSig Technologies (BSGM) Stock Price, News & Analysis

Company Overview

BioSig Technologies, Inc., together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

Key Stats

• Today's Range: $0.50 to $0.57
• 50-Day Range: $0.49 to $1.24
• 52-Week Range: $0.20 to $2.98
• Volume: 412,821 shs
• Average Volume: 421,520 shs
• Market Capitalization: $9.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.75
• Consensus Rating: Buy

BioSig Technologies Stock Analysis - MarketRank™

BioSig Technologies scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

BioSig Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BioSig Technologies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioSig Technologies are expected to grow in the coming year, from ($0.88) to ($0.73) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BSGM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioSig Technologies does not currently pay a dividend.

Dividend Growth

BioSig Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BSGM.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

BioSig Technologies has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BioSig Technologies this week, compared to 0 articles on an average week.

MarketBeat Follows

Only 1 people have added BioSig Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioSig Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.03% of the stock of BioSig Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.16% of the stock of BioSig Technologies is held by institutions.

BSGM Stock Analysis - Frequently Asked Questions

How have BSGM shares performed this year?

BioSig Technologies' stock was trading at $1.49 at the beginning of 2025. Since then, BSGM shares have decreased by 64.6% and is now trading at $0.5280.
View the best growth stocks for 2025 here.

How were BioSig Technologies' earnings last quarter?

BioSig Technologies, Inc. (NASDAQ:BSGM) announced its quarterly earnings results on Thursday, March, 31st. The company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($2.20) by $0.20.

When did BioSig Technologies' stock split?

BioSig Technologies's stock reverse split before market open on Friday, February 2nd 2024. The 1-10 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are BioSig Technologies' major shareholders?

BioSig Technologies' top institutional shareholders include Legacy Investment Solutions LLC (20.90%), Millennium Management LLC (0.89%), PFG Investments LLC (0.64%) and Geode Capital Management LLC (0.56%). Insiders that own company stock include Kenneth L Londoner, Steve Chaussy, Patrick Joseph Gallagher, John Sieckhaus and Gray Fleming.
View institutional ownership trends.

How do I buy shares of BioSig Technologies?

Shares of BSGM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioSig Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioSig Technologies investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Citius Pharmaceuticals (CTXR), Roku (ROKU) and Ford Motor (F).

Company Calendar

• Last Earnings: 3/31/2022
• Today: 3/26/2025
• Next Earnings (Estimated): 4/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BSGM
• CIK: 1530766
• Web: www.biosig.com
• Phone: (230) 409-5444
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.75
• High Stock Price Target: $2.75
• Low Stock Price Target: $2.75
• Potential Upside/Downside: +420.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,040,000.00
• Net Margins: -44,832.50%
• Pretax Margin: -39,405.12%
• Return on Equity: N/A
• Return on Assets: -776.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.50
• Quick Ratio: 0.50

Sales & Book Value

• Annual Sales: $39,000.00
• Price / Sales: 233.34
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.33) per share
• Price / Book: -1.60

Miscellaneous

• Outstanding Shares: 17,235,000
• Free Float: 14,300,000
• Market Cap: $9.10 million
• Optionable: No Data
• Beta: 0.43